Astragalus membranaceus Bunge,known as Huangqi,has been used to treat various diseases for a long time.AstragalosideⅣ(AS-Ⅳ)is one of the primary active ingredients of the aqueous Huangqi extract.Many experimental mo...Astragalus membranaceus Bunge,known as Huangqi,has been used to treat various diseases for a long time.AstragalosideⅣ(AS-Ⅳ)is one of the primary active ingredients of the aqueous Huangqi extract.Many experimental models have shown that AS-Ⅳexerts broad beneficial effects on cardiovascular disease,nervous system diseases,lung disease,diabetes,organ injury,kidney disease,and gynaecological diseases.This review demonstrates and summarizes the structure,solubility,pharmacokinetics,toxicity,pharmacological effects,and autophagic mechanism of AS-Ⅳ.The autophagic effects are associated with multiple signalling pathways in experimental models,including the PI3KI/Akt/m TOR,PI3KⅢ/Beclin-1/Bcl-2,PI3K/Akt,AMPK/m TOR,PI3K/Akt/m TOR,SIRT1–NF-κB,PI3K/AKT/AS160,and TGF-β/Smad signalling pathways.Based on this evidence,AS-Ⅳcould be used as a replacement therapy for treating the multiple diseases referenced above.展开更多
Heart failure has become a global public health problem that seriously threatens human health.Due to "multi-target" effect,traditional Chinese medicine has unique advantages in the treat.ment of heart failur...Heart failure has become a global public health problem that seriously threatens human health.Due to "multi-target" effect,traditional Chinese medicine has unique advantages in the treat.ment of heart failure.Astragaloside Ⅳ is one of the main active ingredients of astragalus membrana.ceus.It has the functions of protecting the heart and neovascularization,anti-inflammation,anti-oxida.tion,regulating energy metabolism,neuroprotection and anti-cancer effects.This article reviews the recent progresses of astragaloside Ⅳ in the treatment of heart failure.Data show that astragaloside Ⅳ can inhibit heart fibrosis,attenuate excessively activation of renin-angiotensin system,increase energy metabolism,promote positive inotropic action,inhibit myocardial cell apoptosis,etc,which are all involved in the protective role of astragalosideⅣ in rodents or cellular models of heart failure.Astragalo.side Ⅳ may be a potential active ingredient in traditional Chinese medicine for the treatment of heart failure.展开更多
目的采用高效液相色谱-四极杆飞行时间串联质谱(HPLC-Q-TOF-MS/MS)挖掘益肾化湿颗粒的主要成分,并结合网络药理学探究益肾化湿颗粒治疗IgA肾病的作用靶点及机制。方法采用质谱技术对益肾化湿颗粒主要成分进行准确定性,并运用TCMSP、ETCM...目的采用高效液相色谱-四极杆飞行时间串联质谱(HPLC-Q-TOF-MS/MS)挖掘益肾化湿颗粒的主要成分,并结合网络药理学探究益肾化湿颗粒治疗IgA肾病的作用靶点及机制。方法采用质谱技术对益肾化湿颗粒主要成分进行准确定性,并运用TCMSP、ETCM、SymMAP数据库获得活性成分靶点;采用GeneCards、OMIM等数据库获得IgA肾病的疾病靶点,对药效疾病靶点进行基因本体(gene ontology,GO)富集分析及京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)通路分析,进一步运用Cytoscape_v3.8.2构建“活性成分-靶点-通路”网络;应用Atuodock软件对筛选靶点及主要活性成分进行分子对接,进行结合位点模拟验证。结果共鉴定出益肾化湿颗粒主要成分68个,包括香豆素类、三萜类和黄酮类等化合物;共获得益肾化湿颗粒治疗IgA肾病活性成分43个,活性成分与疾病交集靶点74个,其中包括过氧化物酶体增殖物激活受体γ、皮质醇受体基因等;涉及通路包括肿瘤坏死因子信号通路、磷脂酰肌醇3激酶/蛋白激酶B信号通路、晚期糖基化产物-晚期糖基化终末产物受体信号通路等。分子对接结果显示,柴胡皂苷A、黄芪甲苷III、黄芪甲苷IV、泽泻醇A与IgA肾病的预测靶点有良好的结合活性。结论益肾化湿颗粒能够通过抗炎、调节免疫、改善类固醇效应等治疗IgA肾病,具有多成分、多靶点、多途径的特点。展开更多
基金Supported by Project of Zhejiang Traditional Chinese Medicine Technology,No.2018ZA063Chinese National Natural and Science Foundation,No.81700552Natural Science Fund Committee of Zhejiang Province,No.LQ20C200010。
文摘Astragalus membranaceus Bunge,known as Huangqi,has been used to treat various diseases for a long time.AstragalosideⅣ(AS-Ⅳ)is one of the primary active ingredients of the aqueous Huangqi extract.Many experimental models have shown that AS-Ⅳexerts broad beneficial effects on cardiovascular disease,nervous system diseases,lung disease,diabetes,organ injury,kidney disease,and gynaecological diseases.This review demonstrates and summarizes the structure,solubility,pharmacokinetics,toxicity,pharmacological effects,and autophagic mechanism of AS-Ⅳ.The autophagic effects are associated with multiple signalling pathways in experimental models,including the PI3KI/Akt/m TOR,PI3KⅢ/Beclin-1/Bcl-2,PI3K/Akt,AMPK/m TOR,PI3K/Akt/m TOR,SIRT1–NF-κB,PI3K/AKT/AS160,and TGF-β/Smad signalling pathways.Based on this evidence,AS-Ⅳcould be used as a replacement therapy for treating the multiple diseases referenced above.
文摘Heart failure has become a global public health problem that seriously threatens human health.Due to "multi-target" effect,traditional Chinese medicine has unique advantages in the treat.ment of heart failure.Astragaloside Ⅳ is one of the main active ingredients of astragalus membrana.ceus.It has the functions of protecting the heart and neovascularization,anti-inflammation,anti-oxida.tion,regulating energy metabolism,neuroprotection and anti-cancer effects.This article reviews the recent progresses of astragaloside Ⅳ in the treatment of heart failure.Data show that astragaloside Ⅳ can inhibit heart fibrosis,attenuate excessively activation of renin-angiotensin system,increase energy metabolism,promote positive inotropic action,inhibit myocardial cell apoptosis,etc,which are all involved in the protective role of astragalosideⅣ in rodents or cellular models of heart failure.Astragalo.side Ⅳ may be a potential active ingredient in traditional Chinese medicine for the treatment of heart failure.
文摘黄芪甲苷是源于蒙古黄芪Astragalus membranaceus(Fisch.)Bge.var.mongholicus(Bge.)Hsiao的三萜苷类成分,具备阻断细胞凋亡、抗炎症反应、抑制氧化应激、减轻肾纤维化、改善贫血、阻滞肿瘤发展等功效,在临床肾病应用方面有着良好的潜力。于调控细胞凋亡及蛋白层面,黄芪甲苷可经改善线粒体损伤、抑制内质网应激、维护裂孔蛋白稳定以阻滞足细胞凋亡;于抗炎性因子及炎症小体方面,黄芪甲苷把控上下级信号通路,束缚炎性因子和炎症小体的释放;于清除氧化自由基层面,黄芪甲苷通过减弱氧化反应、增强抗氧化效应来避免自由基积累,且能消弭内外毒素诱导的急慢性肾损伤;于抑制肾组织纤维化方面,黄芪甲苷降低纤维化因子的过表达,扭转上皮—间充质转化(epithelial to mesenchymal transition,EMT)以推迟肾纤维化进程。本文旨在探究黄芪甲苷治疗肾脏疾病药理作用的最新进展,为进一步实验和临床研究提供参考。
文摘目的采用高效液相色谱-四极杆飞行时间串联质谱(HPLC-Q-TOF-MS/MS)挖掘益肾化湿颗粒的主要成分,并结合网络药理学探究益肾化湿颗粒治疗IgA肾病的作用靶点及机制。方法采用质谱技术对益肾化湿颗粒主要成分进行准确定性,并运用TCMSP、ETCM、SymMAP数据库获得活性成分靶点;采用GeneCards、OMIM等数据库获得IgA肾病的疾病靶点,对药效疾病靶点进行基因本体(gene ontology,GO)富集分析及京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)通路分析,进一步运用Cytoscape_v3.8.2构建“活性成分-靶点-通路”网络;应用Atuodock软件对筛选靶点及主要活性成分进行分子对接,进行结合位点模拟验证。结果共鉴定出益肾化湿颗粒主要成分68个,包括香豆素类、三萜类和黄酮类等化合物;共获得益肾化湿颗粒治疗IgA肾病活性成分43个,活性成分与疾病交集靶点74个,其中包括过氧化物酶体增殖物激活受体γ、皮质醇受体基因等;涉及通路包括肿瘤坏死因子信号通路、磷脂酰肌醇3激酶/蛋白激酶B信号通路、晚期糖基化产物-晚期糖基化终末产物受体信号通路等。分子对接结果显示,柴胡皂苷A、黄芪甲苷III、黄芪甲苷IV、泽泻醇A与IgA肾病的预测靶点有良好的结合活性。结论益肾化湿颗粒能够通过抗炎、调节免疫、改善类固醇效应等治疗IgA肾病,具有多成分、多靶点、多途径的特点。
